Trial Profile
Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs PEPIDH1M (Primary) ; Diphtheria-tetanus vaccine; Diphtheria-tetanus vaccine; Temozolomide
- Indications Glioma
- Focus Adverse reactions
- Acronyms RESIST
- 11 May 2020 Planned End Date changed from 1 Feb 2020 to 1 Dec 2022.
- 18 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Feb 2020.
- 18 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Feb 2020.